Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endogenous modification of the chemoattractant CXCL5 alters receptor usage and enhances its activity toward neutrophils and monocytes.
Metzemaekers M, Mortier A, Vacchini A, Boff D, Yu K, Janssens R, Farina FM, Milanesi S, Berghmans N, Pörtner N, Van Damme J, Allegretti M, Teixeira MM, Locati M, Borroni EM, Amaral FA, Proost P. Metzemaekers M, et al. Among authors: allegretti m. Sci Signal. 2021 Mar 9;14(673):eaax3053. doi: 10.1126/scisignal.aax3053. Sci Signal. 2021. PMID: 33688078
Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
Piemonti L, Keymeulen B, Gillard P, Linn T, Bosi E, Rose L, Pozzilli P, Giorgino F, Cossu E, Daffonchio L, Goisis G, Ruffini PA, Maurizi AR, Mantelli F, Allegretti M. Piemonti L, et al. Among authors: allegretti m. Diabetes Obes Metab. 2022 Sep;24(9):1840-1849. doi: 10.1111/dom.14770. Epub 2022 Jul 4. Diabetes Obes Metab. 2022. PMID: 35589610 Free PMC article. Clinical Trial.
Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants.
Iaconis D, Bordi L, Matusali G, Talarico C, Manelfi C, Cesta MC, Zippoli M, Caccuri F, Bugatti A, Zani A, Filippini F, Scorzolini L, Gobbi M, Beeg M, Piotti A, Montopoli M, Cocetta V, Bressan S, Bucci EM, Caruso A, Nicastri E, Allegretti M, Beccari AR. Iaconis D, et al. Among authors: allegretti m. Cell Death Dis. 2022 May 25;13(5):498. doi: 10.1038/s41419-022-04961-z. Cell Death Dis. 2022. PMID: 35614039 Free PMC article.
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer.
Piro G, Carbone C, Agostini A, Esposito A, De Pizzol M, Novelli R, Allegretti M, Aramini A, Caggiano A, Granitto A, De Sanctis F, Ugel S, Corbo V, Martini M, Lawlor RT, Scarpa A, Tortora G. Piro G, et al. Among authors: allegretti m. Br J Cancer. 2023 Jan;128(2):331-341. doi: 10.1038/s41416-022-02028-6. Epub 2022 Nov 16. Br J Cancer. 2023. PMID: 36385556 Free PMC article.
Bioengineered Human Stromal Lenticule for Recombinant Human Nerve Growth Factor Release: A Potential Biocompatible Ocular Drug Delivery System.
Mastropasqua L, Nubile M, Acerra G, Detta N, Pelusi L, Lanzini M, Mattioli S, Santalucia M, Pietrangelo L, Allegretti M, Dua HS, Mehta JS, Pandolfi A, Mandatori D. Mastropasqua L, et al. Among authors: allegretti m. Front Bioeng Biotechnol. 2022 Jun 23;10:887414. doi: 10.3389/fbioe.2022.887414. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35813999 Free PMC article.
Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.
Pace E, Cerveri I, Lacedonia D, Paone G, Sanduzzi Zamparelli A, Sorbo R, Allegretti M, Lanata L, Scaglione F. Pace E, et al. Among authors: allegretti m. Pharmaceutics. 2022 Jun 14;14(6):1261. doi: 10.3390/pharmaceutics14061261. Pharmaceutics. 2022. PMID: 35745833 Free PMC article. Review.
156 results